Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526509 · ClinicalTrials.gov registry record · Phase 1
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
A Phase 1 study, sponsored by Adaptimmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04526509 is a Phase 1 study that was terminated before completion, run by Adaptimmune. The registered enrollment target is 12 participants.
The verdict
NCT04526509, a Phase 1 study, was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG GSK3845097
- DRUG GSK3901961
- DRUG GSK4427296
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04526509
The ClinicalTrials.gov registry entry for NCT04526509 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04526509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04526509 about?
NCT04526509 is a clinical study titled "Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors". This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
What is the current status of trial NCT04526509?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-12-21. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT04526509?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), GSK3845097 (DRUG), GSK3901961 (DRUG), GSK4427296 (DRUG).
Who is sponsoring clinical trial NCT04526509?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.